ライフサイエンスコーパス: cynomolgus

1 t CP 55 940 in Old World monkeys (rhesus and cynomolgus), a species that has been used extensively in

2 over 6months at sufficient levels to protect Cynomolgus against laser-induced grade IV choroidal neov

3 he key host factor limiting HBV infection in cynomolgus and rhesus macaques and in pigs.

4 Both cynomolgus and rhesus macaques developed mild fevers aft

5 gene expression in the genital tract in both cynomolgus and rhesus macaques.

6 Resistance decreased in both cynomolgus and rhesus monkeys as total volume perfused i

7 lities of the three macaque species (rhesus, cynomolgus, and bonnet) used.

8 We show for the first time that the mouse, cynomolgus, and human cross-reactive, antagonistic anti-

9 we engineered pH-sensitive binding to mouse, cynomolgus, and human PCSK9 into J16, resulting in J17.

10 A similarly selected anti-cynomolgus CD40 dAb recognizing the homologous epitope i

11 owed decreased binding affinity to human and cynomolgus FcgammaRs compared with the wild-type IgG1 an

12 structures of AFD in complex with human and cynomolgus FD (at 2.4 and 2.3 A, respectively) revealed

13 To balance this shift toward activation, the cynomolgus inhibitory FcgammaRIIb shows strongly increas

14 sults in prolonged, drug-free engraftment of cynomolgus islet allografts.

15 ll group of male rhesus (Macaca mulatta) and cynomolgus (Macaca fascicularis) macaques with a minimal

16 nd gut-brain metabolic signatures, in female cynomolgus macaque (Macaca fascicularis) displaying natu

17 We used the cynomolgus macaque (Macaca fascicularis) model of HIV-My

18 The cynomolgus macaque (Macaca fascicularis) model of M. tub

19 We developed an intradermal (ID) challenge cynomolgus macaque (Macaca fascicularis) model of scrub

20 Using the cynomolgus macaque (Macaca fascicularis) to assess prima

21 thiops), rhesus macaque (Macaca mulatta) and cynomolgus macaque (Macaca fascicularis), all male.

22 mental studies of IOP dynamics and glaucoma: cynomolgus macaque (Macaca fascicularis), rhesus macaque

23 ectomized non-human primate (NHP) model, the cynomolgus macaque (Macaca fascicularis).

24 yed-type hypersensitivity (DTH) model in the cynomolgus macaque (Macaca fascicularis).

25 the utility of cigarette smoke (CS)-exposed cynomolgus macaque as a nonhuman primate (NHP) large ani

26 Male cynomolgus macaque donor-recipient pairs were selected b

27 ow that TGN1412 binds similarly to human and cynomolgus macaque FcgammaR, eliminating the possibility

28 Inhalational plague in the cynomolgus macaque inoculated by the aerosol route produ

29 incidence and treatment of CMV viremia in a Cynomolgus macaque model of bone marrow transplantation

30 We used the cynomolgus macaque model of TB to demonstrate that ex vi

31 evaluated the gene expression changes in the cynomolgus macaque model of TB, which recapitulates all

32 ociated with arenavirus virulence, we used a cynomolgus macaque model to evaluate the pathogenesis of

33 We applied this strategy in a Cynomolgus macaque model.

34 gnatures of cell types between human and the cynomolgus macaque monkey, Macaca fascicularis.

35 of EBOV infection, EBOTAb was tested in the cynomolgus macaque non-human primate model of lethal EBO

36 in Rhesus macaques of Indian genotype (RM), cynomolgus macaque of Chinese genotype (CCM) and cynomol

37 molgus macaque of Chinese genotype (CCM) and cynomolgus macaque of Mauritian genotype (MCM), which fo

38 he KIR region in large cohorts of rhesus and cynomolgus macaque populations were characterized, and t

39 he first time, to our knowledge, that LCs in cynomolgus macaque skin are capable of inducing antivira

40 on of a natural classical scrapie isolate to cynomolgus macaque, a highly relevant model for human pr

41 The cynomolgus macaque, Macaca fascicularis, was introduced

42 , using iPSCs derived from an MHC homozygous cynomolgus macaque.

43 ion in other species, we compared T cells of cynomolgus macaques (CMs) infected with wild-type Simian

44 ermline-transmissible mutations of SHANK3 in cynomolgus macaques (Macaca fascicularis) and their F1 o

45 HBV-positive markers were detected in cynomolgus macaques (Macaca fascicularis) from Mauritius

46 Compared to cynomolgus macaques (Macaca fascicularis) infected with

47 socricetus auratus), mice (Mus musculus) and cynomolgus macaques (Macaca fascicularis), and-concomita

48 campal bioenergetic capacity in adult female cynomolgus macaques (Macaca fascicularis).

49 However, here we report that Mauritian cynomolgus macaques (MCM), Macaca fascicularis, vaccinat

50 pecific CD8 T cells from SIV-naive Mauritian cynomolgus macaques (MCM).

51 in rhesus macaques (RM) and Mauritian-origin cynomolgus macaques (MCM).

52 nses to Mycobacterium tuberculosis Mauritian cynomolgus macaques (MCMs) are a unique group of animals

53 model for many human diseases, and Mauritian cynomolgus macaques (MCMs) are particularly useful becau

54 nce variants in SIVmac239-infected Mauritian cynomolgus macaques (MCMs) that are homozygous for the M

55 immunodeficiency virus (SIV) from Mauritian cynomolgus macaques (MCMs) that were homozygous and hete

56 Mauritian cynomolgus macaques (MCMs), with high degree of MHC alle

57 Adult male Cynomolgus macaques (n = 6) were surgically implanted to

58 In this study, we used male cynomolgus macaques (n=15) living in established social

59 Cynomolgus macaques 4 years of age or older were infecte

60 Using voltammetry in brain slices from cynomolgus macaques after 6 months of ad libitum ethanol

61 ival of SUDV challenge did not fully protect cynomolgus macaques against intramuscular EBOV back-chal

62 ded greater than 80% protection to Mauritian cynomolgus macaques against repeated intravaginal SIVmac

63 Cynomolgus macaques are an excellent animal model for ma

64 Here we show that both rhesus and cynomolgus macaques are highly susceptible to infection

65 CyTOF Abs to compare the B cell response in cynomolgus macaques at baseline, and 8 and 28 d after th

66 n understanding ZEBOV-Makona pathogenesis in cynomolgus macaques by measuring changes in immune cell

67 Neutralization of TNF in latently infected cynomolgus macaques caused reactivation in a majority of

68 h BCG delays and reduces clinical disease in cynomolgus macaques challenged with M. tuberculosis and

69 8beta-specific depleting mAb CD8beta255R1 to cynomolgus macaques chronically infected with a LASIV to

70 tuberculosis infection, equal proportions of cynomolgus macaques develop active disease or latent inf

71 Control cynomolgus macaques developed fever, classic eschars, ly

72 IL-10, we used an Ab to neutralize IL-10 in cynomolgus macaques during M. tuberculosis infection.

73 h no other severe outcomes, whereas infected cynomolgus macaques experienced only mild/ moderate anae

74 We studied cynomolgus macaques exposed to Ebola virus Makona via di

75 ost importantly, BCX4430 completely protects cynomolgus macaques from Marburg virus infection when ad

76 tions and event-related potentials (ERPs) in Cynomolgus macaques fully trained to perform a continuou

77 studies which illustrate how the rhesus and cynomolgus macaques have enriched and may continue to ad

78 tion of different human smallpox vaccines in cynomolgus macaques helps to provide information about o

79 us monoclonal antibodies (MAbs) derived from cynomolgus macaques immunized repeatedly with a mixture

80 inistration of the equine IgG over 5 days to cynomolgus macaques infected 24 hours previously with a

81 Cynomolgus macaques infected ocularly with a trachoma st

82 In cynomolgus macaques infected with a low dose of M. tuber

83 Cynomolgus macaques infected with low-dose Mycobacterium

84 riable course of disease is recapitulated in cynomolgus macaques infected with Mtb.

85 t on natural, persisting HBV infection among cynomolgus macaques provides the first evidence for the

86 M. tuberculosis infection in cynomolgus macaques recapitulates essentially all aspect

87 Seven cynomolgus macaques received immune conditioning followe

88 ose challenge with fully virulent strains in cynomolgus macaques result in the full clinical spectrum

89 ation of aerosolized H5N1 influenza virus in cynomolgus macaques results in fulminant pneumonia that

90 ious genetic studies have reported Mauritian cynomolgus macaques to be panmictic, the individuals inc

91 zation (IVF) methods established for Chinese cynomolgus macaques to generate in vitro MCM embryos.

92 ntibodies from vaccinated Ebola virus-immune cynomolgus macaques to naive macaques failed to confer p

93 1 viruses and compared the host responses of cynomolgus macaques to the virus infection.

94 Cynomolgus macaques vaccinated with COBRA clade 2 HA H5N

95 Disease caused by MARV in cynomolgus macaques was very similar to disease previous

96 Groups of cynomolgus macaques were depleted of CD4+ T, CD8+ T, or

97 Cynomolgus macaques were exposed by inhalation to approx

98 Cynomolgus macaques were exposed to aerosolized monkeypo

99 Eight Mauritian derived, MHC-typed cynomolgus macaques were immunised with 10(5) TCID(50) o

100 Nine cynomolgus macaques were immunized and boosted with the

101 Cynomolgus macaques were infected with MARV Angola and m

102 mice, rats, dogs, pigs, rhesus macaques, and cynomolgus macaques were transduced with adeno-associate

103 Beginning 4 or 5 days post inoculation, cynomolgus macaques were treated once daily for 12 days

104 Cynomolgus macaques were vaccinated twice with the quadr

105 Cynomolgus macaques were vaccinated with a DNA-based vac

106 ) protected 67% (6 of 9) and 25% (1 of 4) of cynomolgus macaques when administered 30 minutes and 24

107 VRP expressing SUDV GP completely protected cynomolgus macaques when challenged with aerosolized SUD

108 des of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advan

109 w that chemoprophylaxis of latently infected cynomolgus macaques with 6 mo of isoniazid (INH) effecti

110 Vaccination of cynomolgus macaques with a single dose of either vaccine

111 cumulation of mutations in Mtb isolated from cynomolgus macaques with active, latent or reactivated d

112 induce severe disease in humans, we infected cynomolgus macaques with six different H5N1 strains isol

113 infected MHC-homozygous and MHC-heterozygous cynomolgus macaques with the pathogenic virus SIVmac239.

114 Intratracheal infection of cynomolgus macaques with these recombinant viruses revea

115 A single intramuscular vaccination of cynomolgus macaques with VRP expressing SUDV GP provided

116 an primates (NHPs; African green monkeys and cynomolgus macaques) harbor serosal B cells expressing a

117 brains of rats and adult nonhuman primates (cynomolgus macaques).

118 In cynomolgus macaques, a bolus injection of di-siRNA showe

119 investigated the effects of TAAR1 agonism in Cynomolgus macaques, a diurnal species that exhibits con

120 veloped a greater inflammatory response than cynomolgus macaques, and had lower baseline levels of CD

121 infusion on the immunological composition in cynomolgus macaques, compared to an isotype-matched cont

122 ection rapidly and profoundly impacts DCs in cynomolgus macaques, increasing the number of blood myel

123 uted tomography and near-infrared imaging of cynomolgus macaques, of the trafficking dynamics to drai

124 Contrarily, hepatocytes from cynomolgus macaques, rhesus macaques, and pigs became fu

125 ons derived from RNA-seq data for rhesus and cynomolgus macaques, two of the most commonly used NHP m

126 g MHC-homozygous and -heterozygous Mauritian cynomolgus macaques, we have now obtained evidence that

127 ly restricted genetic diversity of Mauritian cynomolgus macaques, we performed adoptive transfers bet

128 smallpox, a monkeypox model of infection in cynomolgus macaques, which simulates smallpox in humans,

129 nhances the activity of LCAT from humans and cynomolgus macaques.

130 We developed an assay to monitor CMV in Cynomolgus macaques.

131 on between Lujo and Lassa virus infection in cynomolgus macaques.

132 ods after experimental infection in mice and cynomolgus macaques.

133 pecific CD8 T cells from SIV-naive Mauritian cynomolgus macaques.

134 ues, which were collected from EBOV-infected cynomolgus macaques.

135 ema toxin after pulmonary spore challenge of cynomolgus macaques.

136 agglutinin (HA) and/or nucleoprotein (NP) in cynomolgus macaques.

137 idually or in combination (V/W/E) to mice or cynomolgus macaques.

138 e conserved across FcgammaRIIb of rhesus and cynomolgus macaques.

139 assa fever: inbred strain 13 guinea pigs and cynomolgus macaques.

140 scular challenge with either SUDV or EBOV in cynomolgus macaques.

141 cell responses in acutely infected Mauritian cynomolgus macaques.

142 in combination, via the intranasal route in cynomolgus macaques.

143 lammatory cytokine release in the airways of cynomolgus macaques.

144 cell responses in MHC-I homozygous Mauritian cynomolgus macaques.

145 e and creatine kinase serum enzyme levels in cynomolgus macaques.

146 tion against lethal EBOV-Makona challenge in cynomolgus macaques.

147 tissues collected from EBOV-Makona-infected cynomolgus macaques.

148 nrelated, fully MHC-matched Mauritian-origin cynomolgus macaques.

149 olume in behaviorally depressed adult female cynomolgus macaques; the mechanisms contributing to that

150 ariants conferring extended plasma t1/2 In a cynomolgus model of T cell-dependent Ab response, the CT

151 One cynomolgus monkey (4.5 kg, intravenous ketamine/xylazine

152 Here, we analyzed cynomolgus monkey (CM) iPSC-derived midbrain dopamine ne

153 ve state in a non-human primate species, the cynomolgus monkey (Macaca fascicularis), in a realistic

154 were validated in DSM-denuded bladder of the cynomolgus monkey (Macaca fascicularis).

155 s, exemplified by compound 52, in an in vivo cynomolgus monkey acute adrenocorticotropic hormone (ACT

156 264RAD cross-reacts with human, mouse and cynomolgus monkey alphavbeta6, and inhibits binding to a

157 omolgus monkey of those derivatives with low cynomolgus monkey and human intrinsic clearance gave 2',

158 flammatory cytokine induction pathway in the cynomolgus monkey and humans, but not observed systemica

159 and intravenous administration of NgR1-Fc to cynomolgus monkey and to rat are without evident toxicit

160 to 10,000-fold for CYP1A1 in vivo in rat and cynomolgus monkey and up to 45-fold for CYP1A1 and CYP1A

161 kGH was administered to mice, rabbits, and a cynomolgus monkey by subcutaneous or intradermal injecti

162 lture system that enabled the development of cynomolgus monkey embryos in vitro for up to 20 days.

163 o three target sites across 11 genes/loci in cynomolgus monkey embryos using CRISPR-based cytidine- a

164 lecules and their SEFL variants to human and cynomolgus monkey FcgammaRs were evaluated using flow cy

165 ng and cross-species comparisons with mouse, cynomolgus monkey gastrulae, and post-implantation human

166 ults for human IgG2 and IgG4 obtained in the cynomolgus monkey have to be cautiously interpreted, whe

167 Cynomolgus monkey heterotopic cardiac allograft recipien

168 nd effector functions, whereas, in contrast, cynomolgus monkey IgG2 and IgG4 display strong effector

169 dies were assessed in a variety of human and cynomolgus monkey in vitro assays.

170 -MS/MS assay for quantification of human and cynomolgus monkey interleukin 21 (IL-21) was developed,

171 t/CRISPR-associated nuclease 9 to generate a cynomolgus monkey model by disrupting SHANK3 at exons 6

172 In an acute cynomolgus monkey model of interleukin 6 (IL-6)-induced

173 el of fatal tuberculosis and the established cynomolgus monkey model to design an immuno-chemotherape

174 One live delivery of a female cynomolgus monkey occurred after 162 days of gestation,

175 pharmacokinetic profile in the rat, dog, and cynomolgus monkey of those derivatives with low cynomolg

176 ical' smooth muscle cells) in the murine and cynomolgus monkey pelvis-kidney junction.

177 totoxicity in vitro against Daudi cells with cynomolgus monkey peripheral blood mononuclear cells, an

178 dentified in 96 h and 168 h postdose in vivo cynomolgus monkey plasma.

179 antibody-dependent monocyte phagocytosis of cynomolgus monkey platelets, and cynomolgus platelet act

180 Cynomolgus monkey recipients of life-supporting kidney a

181 uence of alemtuzumab (i) on ex vivo-expanded cynomolgus monkey regulatory T cells (Treg) generated fo

182 say was developed and qualified in human and cynomolgus monkey serum and tissues with a lower limit o

183 uantify a recombinant monoclonal antibody in cynomolgus monkey serum.

184 However, IL-21 levels were quantified in cynomolgus monkey spleen and colon tissue and normal and

185 ime profile after oral administration in the cynomolgus monkey that showed a very low peak-to-trough

186 Thus, expanded cynomolgus monkey Treg are resistant to alemtuzumab-medi

187 inds with high affinity to mouse, human, and cynomolgus monkey VISTA.

188 the pharmacokinetic study of a mAb dosed in cynomolgus monkey, and the results were compared with th

189 d 8 has good oral bioavailability in rat and cynomolgus monkey, attractive overall preclinical proper

190 A PET study was performed on a cynomolgus monkey.

191 erated and confirmed to be cross-reactive to cynomolgus monkey.

192 IIb, but show higher levels of FcgammaRII in cynomolgus monkey.

193 gG1 antibody to oxidized LDL (anti-oxLDL) in cynomolgus monkey.

194 n promising oral bioavailability in rats and cynomolgus monkey.

195 inding, and radiation dosimetry in a healthy cynomolgus monkey.

196 cine and human therapeutic Ab development in cynomolgus monkeys (cynos) are influenced by immune resp

197 ic (PK) behavior of monoclonal antibodies in cynomolgus monkeys (cynos) is generally translatable to

198 its a robust acute pharmacodynamic effect in cynomolgus monkeys (ED50 0.12 mg/kg) and in DIO mice.

199 isms of spread, we infected groups of 5 or 6 cynomolgus monkeys (Macaca fascicularis) with either a w

200 ropic Mycoplasma sp. in a research colony of cynomolgus monkeys (Macaca fascicularis).

201 injected into the mammillary bodies of five cynomolgus monkeys (Macaca fascicularis).

202 receptor availability was assessed in female cynomolgus monkeys (n = 16) with positron emission tomog

203 In a group of cocaine-experienced male cynomolgus monkeys (N=4), THC SA was examined under a se

204 istered to healthy mice by oral gavage or to cynomolgus monkeys (nonhuman primates) by colonic spray

205 e performed in rats (organ distribution) and cynomolgus monkeys (PET/CT imaging) to determine the GLP

206 ure perfusion in one eye of 22 rhesus and 17 cynomolgus monkeys (ranging in age, respectively, from 4

207 the utility of preclinical species, rats and cynomolgus monkeys [nonhuman primates (NHPs)], to predic

208 e target tissues, liver, and adipose, and in cynomolgus monkeys a 10 mg/kg oral dose reduced cortisol

209 Cynomolgus monkeys administered ISIS 416858 (4, 8, 12, a

210 n and thrombus detection was investigated in cynomolgus monkeys after insertion of a roughened cathet

211 f NiV (Malaysia, Bangladesh) was assessed in cynomolgus monkeys and compared with henipavirus-infecte

212 r experience with severe sepsis in two young cynomolgus monkeys and five pigs that were subjected to

213 ormed 305 ovarian stimulations in 128 female cynomolgus monkeys and found that ovarian stimulation ca

214 of (11)C-Lu AE92686 in the striatum of both cynomolgus monkeys and humans were evaluated by the simp

215 or PDE10A-expressing regions in the brain of cynomolgus monkeys and humans.

216 6 was evaluated as a PET tracer candidate in cynomolgus monkeys and in humans.

217 TT30 selectively inhibits CAP in cynomolgus monkeys and is bioavailable after subcutaneou

218 erapy functionality of SiGdNP were tested in cynomolgus monkeys and pancreatic tumor-bearing mice mod

219 ound 6 had minimal effect on HDL-C levels in cynomolgus monkeys and showed human cadaver skin permeab

220 ibose (ADPR) and ADP in colonic muscles from cynomolgus monkeys and wild-type (CD38(+/+)) and CD38(-/

221 bust and sustained anticoagulant activity in cynomolgus monkeys as assessed by activated partial thro

222 nge in resistance significantly increased in cynomolgus monkeys as total volume perfused increased (0

223 d higher titers of toxin-neutralizing Abs in cynomolgus monkeys at 2 wk compared with animals immuniz

224 ribution of (125)I-AMG 386 was determined in cynomolgus monkeys by whole-body autoradiography and rad

225 barrier in archival formalin-fixed lungs of cynomolgus monkeys challenged with the fully virulent B.

226 ng data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucag

227 DX-2930 injected subcutaneously into cynomolgus monkeys exhibited a long half-life (t(1/2) ap

228 ered CSF and cortex Abeta40 in both rats and cynomolgus monkeys following a single oral dose.

229 odels required dosing every 48 h, studies in cynomolgus monkeys indicate that less frequent dosing ma

230 The pharmacologic profile in cynomolgus monkeys is equivalent to what was reported in

231 A single administration of 27C3 to cynomolgus monkeys led to a rapid increase of plasma LCA

232 aft SCID mouse model and depletes B cells in cynomolgus monkeys more efficiently.

233 dation of a humanized monoclonal antibody in cynomolgus monkeys over a time period of 12 weeks after

234 Eight cynomolgus monkeys received unilateral intraputamen inje

235 and phenotypes of TALEN-edited MECP2 mutant cynomolgus monkeys serving as a model for a neurodevelop

236 ic studies in human FcRn transgenic mice and cynomolgus monkeys showed that multiple variants with in

237 Administration of bardoxolone methyl to cynomolgus monkeys significantly decreased the protein e

238 , we evaluated T and B cell alloresponses in cynomolgus monkeys that had received combined kidney/bon

239 ST101 were studied in 3xTg-AD mice and young cynomolgus monkeys using a combination of biochemical an

240 development of allergic lung inflammation in cynomolgus monkeys using gene expression profiling and t

241 Cynomolgus monkeys were fed brain of (eleven) cows with

242 Eighteen cynomolgus monkeys were infected with MARV; blood and ti

243 To address this question, cynomolgus monkeys were injected i.v. with two doses of

244 FKB8488A induced marked weight loss in obese cynomolgus monkeys while elevating serum adiponectin and

245 (DKO) pig (and a GGTA1-KO pig) and immunized cynomolgus monkeys with both of these cells.

246 hibits airway tryptase in Ascaris-sensitized cynomolgus monkeys with favorable pharmacokinetics.

247 Interestingly, treatment of cynomolgus monkeys with JNJ-61186372 resulted in no majo

248 PMNs to LukGH was similar between humans and cynomolgus monkeys, and was greater than that of rabbits

249 In cynomolgus monkeys, ARGX-117 dose-dependently reduces fr

250 alyzed 15 pairs of pregnant and non-pregnant cynomolgus monkeys, each pair of which received embryos

251 of B cells prior to heart transplantation in cynomolgus monkeys, in addition to conventional posttran

252 o by binding to endogenous PCSK9 in mice and cynomolgus monkeys, respectively.

253 rance of 19.3 and 15.5 mL/min/kg in rats and cynomolgus monkeys, respectively.

254 In cynomolgus monkeys, SGN-CD19B effectively depleted CD20(

255 In cynomolgus monkeys, the anti-CD28 dAb demonstrated pharm

256 In cynomolgus monkeys, we again observed a short half-life,

257 bies virus-based EBOV vaccine, in rhesus and cynomolgus monkeys.

258 poor pharmacokinetic profile in both rat and cynomolgus monkeys.

259 to identify recently derived retrocopies in cynomolgus monkeys.

260 increased circulating intact FGF21 levels in cynomolgus monkeys.

261 retrocopies, all of which are polymorphic in cynomolgus monkeys.

262 ing strength of cocaine in group-housed male cynomolgus monkeys.

263 erapeutic target for autoimmune diseases, in cynomolgus monkeys.

264 d reduces fever after sublethal challenge in cynomolgus monkeys.

265 administration to lipopolysaccharide-treated cynomolgus monkeys.

266 electrocardiogram parameters in telemetrized cynomolgus monkeys.

267 al mice, mice transgenic for human FcRn, and cynomolgus monkeys.

268 inding protein 2 (MECP2), in both rhesus and cynomolgus monkeys.

269 r cell-mediated killing assay and in vivo in cynomolgus monkeys.

270 tal, 10 PET measurements were conducted on 5 cynomolgus monkeys.

271 I and demonstrated to modulate serum iron in cynomolgus monkeys.

272 on in livers of mice, rats, and dogs but not cynomolgus monkeys.

273 optic nerve margin in the right eyes of four cynomolgus monkeys.

274 hippocampal IRS-1pSer and JNK activation in cynomolgus monkeys.

275 d both blood and bone marrow plasma cells in cynomolgus monkeys.

276 tic cleavage of FGF21 identified in mice and cynomolgus monkeys.

277 ghtly higher than typical IgG1 antibodies in cynomolgus monkeys.

278 e, and selectively reduce LDL-cholesterol in cynomolgus monkeys.

279 labeled material) to two male and two female cynomolgus monkeys.

280 us-sensitive, CD155 transgenic (tg) mice and cynomolgus monkeys.

281 e, after accounting for total volume, in the cynomolgus monkeys.

282 f total volume were determined in rhesus and cynomolgus monkeys.

283 heavy drinking within the inferior olive of cynomolgus monkeys.

284 ogenitor, CAT6001, in a single-dose study in cynomolgus monkeys.

285 netic/pharmacodynamic study was conducted in cynomolgus monkeys.

286 mg/kg of LY2886721, a BACE1 inhibitor, in 2 cynomolgus monkeys.

287 b/CD18 prevents progression of AKI to CKD in cynomolgus monkeys.

288 n of B cells and bone marrow plasma cells in cynomolgus monkeys.

289 ow background after intravenous injection in cynomolgus monkeys.

290 n stimulated gene (ISG) response in mice and cynomolgus monkeys.

291 ld prolonged half-life in mice, rabbits, and cynomolgus monkeys; however, the prolongation was less p

292 plasma from chimpanzees; gorillas; bonobos; cynomolgus monkeys; wild-type, apoE(-/-), LDLR(-/-), and

293 monstration of efficacy in the gold standard cynomolgus or rhesus macaque models of filovirus infecti

294 GLP-1R occupancy in the cynomolgus pancreas after coinjection of DO3A-exendin-4

295 GLP-1R occupancy in the cynomolgus pancreas was quantified with a 1-tissue-compa

296 Results:(18)F-BMS-986192 bound to human and cynomolgus PD-L1 with a dissociation constant of less th

297 ocytosis of cynomolgus monkey platelets, and cynomolgus platelet activation in vitro These experiment

298 ciency virus-infected rhesus with AIDS and 1 cynomolgus post-transplant selected with SV40 brain infe

299 Both the human-specific and cynomolgus-specific molecules remain pure antagonists ev

300 CP2-targeting TALEN plasmids into rhesus and cynomolgus zygotes leads to effective gene editing of ME